![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Teva Pharmaceuticals Axes Phase 2 Asthma Trial
Teva Pharmaceuticals Axes Phase 2 Asthma Trial
Teva Pharmaceuticals has halted a phase 2 trial of TEV-48574, an investigational biologic drug for asthma patients, after interim results indicated that the treatment is unlikely to provide a significant benefit.
The study, which enrolled 65 asthma patients who were randomized to receive either TEV-48574 or placebo, failed to meet the benefit criteria based on several clinical measures, the company said.
Despite the halting of the asthma trial, TEV-48574 is in an ongoing phase 2 study for the treatment of inflammatory bowel disease.
Upcoming Events
-
21Oct